NANOBIOTIX news, videos and press releases
For more news please use our advanced search feature.
NANOBIOTIX - More news...
NANOBIOTIX - More news...
- NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
- Voting Rights and Shares Capital of the Company
- NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
- Voting Rights and Shares Capital of the Company
- Voting Rights and Shares Capital of the Company
- NANOBIOTIX to Participate in Multiple Investor Conferences in November
- Voting Rights and Shares Capital of the Company
- NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
- Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Voting Rights and Shares Capital of the Company
- Voting Rights and Shares Capital of the Company
- Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
- NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
- NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
- Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
- Voting Rights and Shares Capital of the Company
- NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
- NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
- NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
- Nanobiotix to Present at Upcoming Investor Conferences in March
- Voting Rights and Shares Capital of the Company
- Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
- Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
- Voting Rights and Shares Capital of the Company
- Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
- NANOBIOTIX Announces Closing of Global Offering
- NANOBIOTIX Announces Closing of Global Offering
- NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
- NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
- NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
